State of the art of Smo antagonists for cancer therapy: Advances in the target receptor and new ligand structures

Christian Espinosa-Bustos, Jaime Mella, Jorge Soto-Delgado, Cristian O. Salas

Resultado de la investigación: Review article

1 Cita (Scopus)

Resumen

Since the Hedgehog signaling pathway has been associated with cancer, it has emerged as a therapeutic target for cancer therapy. The main target among the key Hedgehog proteins is the GPCR-like Smo receptor. Therefore, some Smo antagonists that have entered clinical trials, including the US FDA-approved drugs vismodegib and sonidegib, to treat basal cell carcinoma and medulloblastoma. However, early resistance of these drugs has spawned the need to understand the molecular bases of this phenomena. We therefore reviewed details about Smo receptor structures and the best Smo antagonist chemical structures. In addition, we discussed strategies that should be considered to develop new, safer generations of Smo antagonists that avoid current clinical limitations.

Idioma originalEnglish
Páginas (desde-hasta)617-638
Número de páginas22
PublicaciónFuture Medicinal Chemistry
Volumen11
N.º6
DOI
EstadoPublished - 1 mar 2019

Huella dactilar

HhAntag691
Hedgehog Proteins
Ligands
Medulloblastoma
Basal Cell Carcinoma
Drug Resistance
Neoplasms
Clinical Trials
Therapeutics
Pharmaceutical Preparations
LDE225

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Citar esto

Espinosa-Bustos, Christian ; Mella, Jaime ; Soto-Delgado, Jorge ; Salas, Cristian O. / State of the art of Smo antagonists for cancer therapy : Advances in the target receptor and new ligand structures. En: Future Medicinal Chemistry. 2019 ; Vol. 11, N.º 6. pp. 617-638.
@article{0916deea503144c8bdf9cf8f1f1fb8bd,
title = "State of the art of Smo antagonists for cancer therapy: Advances in the target receptor and new ligand structures",
abstract = "Since the Hedgehog signaling pathway has been associated with cancer, it has emerged as a therapeutic target for cancer therapy. The main target among the key Hedgehog proteins is the GPCR-like Smo receptor. Therefore, some Smo antagonists that have entered clinical trials, including the US FDA-approved drugs vismodegib and sonidegib, to treat basal cell carcinoma and medulloblastoma. However, early resistance of these drugs has spawned the need to understand the molecular bases of this phenomena. We therefore reviewed details about Smo receptor structures and the best Smo antagonist chemical structures. In addition, we discussed strategies that should be considered to develop new, safer generations of Smo antagonists that avoid current clinical limitations.",
keywords = "anticancer compounds, cancer therapy, Hedgehog signaling pathway, Smo antagonists, Smoothened receptor",
author = "Christian Espinosa-Bustos and Jaime Mella and Jorge Soto-Delgado and Salas, {Cristian O.}",
year = "2019",
month = "3",
day = "1",
doi = "10.4155/fmc-2018-0497",
language = "English",
volume = "11",
pages = "617--638",
journal = "Future Medicinal Chemistry",
issn = "1756-8919",
publisher = "Future Science",
number = "6",

}

State of the art of Smo antagonists for cancer therapy : Advances in the target receptor and new ligand structures. / Espinosa-Bustos, Christian; Mella, Jaime; Soto-Delgado, Jorge; Salas, Cristian O.

En: Future Medicinal Chemistry, Vol. 11, N.º 6, 01.03.2019, p. 617-638.

Resultado de la investigación: Review article

TY - JOUR

T1 - State of the art of Smo antagonists for cancer therapy

T2 - Advances in the target receptor and new ligand structures

AU - Espinosa-Bustos, Christian

AU - Mella, Jaime

AU - Soto-Delgado, Jorge

AU - Salas, Cristian O.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Since the Hedgehog signaling pathway has been associated with cancer, it has emerged as a therapeutic target for cancer therapy. The main target among the key Hedgehog proteins is the GPCR-like Smo receptor. Therefore, some Smo antagonists that have entered clinical trials, including the US FDA-approved drugs vismodegib and sonidegib, to treat basal cell carcinoma and medulloblastoma. However, early resistance of these drugs has spawned the need to understand the molecular bases of this phenomena. We therefore reviewed details about Smo receptor structures and the best Smo antagonist chemical structures. In addition, we discussed strategies that should be considered to develop new, safer generations of Smo antagonists that avoid current clinical limitations.

AB - Since the Hedgehog signaling pathway has been associated with cancer, it has emerged as a therapeutic target for cancer therapy. The main target among the key Hedgehog proteins is the GPCR-like Smo receptor. Therefore, some Smo antagonists that have entered clinical trials, including the US FDA-approved drugs vismodegib and sonidegib, to treat basal cell carcinoma and medulloblastoma. However, early resistance of these drugs has spawned the need to understand the molecular bases of this phenomena. We therefore reviewed details about Smo receptor structures and the best Smo antagonist chemical structures. In addition, we discussed strategies that should be considered to develop new, safer generations of Smo antagonists that avoid current clinical limitations.

KW - anticancer compounds

KW - cancer therapy

KW - Hedgehog signaling pathway

KW - Smo antagonists

KW - Smoothened receptor

UR - http://www.scopus.com/inward/record.url?scp=85064121690&partnerID=8YFLogxK

U2 - 10.4155/fmc-2018-0497

DO - 10.4155/fmc-2018-0497

M3 - Review article

C2 - 30912670

AN - SCOPUS:85064121690

VL - 11

SP - 617

EP - 638

JO - Future Medicinal Chemistry

JF - Future Medicinal Chemistry

SN - 1756-8919

IS - 6

ER -